PHAT · Phathom Pharmaceuticals, Inc.
$5.74
-18.12% last session
End-of-day data · close of 2026-10-23
Market cap
<$1M
Enterprise value
$1B
Trailing P/E
—
Forward P/E
6.0
Dividend yield
0.0%
Beta
0.50
Avg volume
1M
Employees
0K
Daily Change %
-18.12%
5 Days Change
-18.12%
10 Days Change
-22.43%
30 Days Change
-18.93%
60 Days Change
-34.77%
Month to Day Change
-18.93%
Year to Day Change
-65.40%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PHAT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Barclays
Overweight$14.00
+143.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Leerink Partners | Initiates | Market Perform | $0.00 → $10.00 |
| 2026-08-17 | Barclays | Maintains | Overweight | $18.00 → $14.00 |
| 2026-07-31 | Guggenheim | Maintains | Buy | $25.00 → $22.00 |
| 2026-07-31 | HC Wainwright & Co. | Reiterates | Buy | $26.00 |
| 2026-07-30 | Needham | Maintains | Buy | $28.00 → $22.00 |
| 2026-06-17 | HC Wainwright & Co. | Reiterates | Buy | $26.00 |
| 2026-03-27 | Barclays | Upgrade | Equal-Weight → Overweight | $16.00 → $18.00 |
| 2026-02-27 | Guggenheim | Maintains | Buy | $20.00 → $25.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 30 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 27.9% below the 50-day MA ($7.96).
- bearish: Price vs 200-day MA: Trading 46.2% below the 200-day MA ($10.67).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.02) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($5.74).
PHAT Price Chart
Loading chart for PHAT…
Fundamentals
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.